samedan logo
 
 
spacer
home > pmps > winter 2008 > the demand for digital
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Demand for Digital

Christoph Staub at Hapa AG outlines the power of digital print for pharmaceutical packaging and its potential to transform the industry

The onward march of digital technology has had a significant impact on many areas of business, and none more so than on the print sector. Traditional print technologies such as litho have harnessed the power of digital technology in computer-to-print (CTP) processes; and the past decade or so has seen a huge growth in the number of digital presses which eliminate the need for printing plates altogether.

INKJET TECHNOLOGY

First seen in the early 1970s when manufactures and users were seeking a cost-effective and robust alternative to dot matrix printers, inkjet technology is undoubtedly one of the stars of the digital revolution. Due to their low cost, ease of use and impressive colour reproduction capabilities, inkjet printers are now the most commonly-used technology for consumer printing.

In the professional print arena there is a huge market for inkjet printing, with applications generally divided into three categories – proofing, page-width printing and wide format printing. Inkjet proofing has now largely replaced the expensive and time-consuming analogue system of proofing print jobs for colour accuracy before a large volume run. Broadly speaking, page-width applications involve the production of items such as bills and individually-addressed catalogues or magazines, where each item in the run is unique because of the personalised data it carries. Wide format technology is principally used for the production of advertising graphics, such as billboard posters, but as a non-contact technology with a print width of up to five metres, a vast and growing number of applications can be addressed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christoph Staub was appointed Commercial Director for Hapa AG in September 2007, having previously worked for the company for six years during the 1990s when it was part of the Romaco Group. With qualifications in mechanical and business engineering, Christoph has gained over 15 years of experience in the pharmaceutical packaging industry. He is currently responsible for the commercial development of the business including sales and marketing, application engineering and aftermarket. Christoph joined Hapa from Neuronics AG, where he was Head of Marketing and Sales. Prior to this he was Group Sales & Marketing Manager for Romaco AG, and also worked for the Zepter International Group and Disetronic Medical Systems AG
spacer
Christoph Staub
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement